a close up of a pen


Prometic Life Sciences Inc. completes C$61.7M bought deal offering and concurrent private placement

Date closed: 7/6/2017

Value: C$61.7 million

On July 6, 2017, Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic or the Corporation) completed its $53.1 million bought deal equity offering of common shares in the capital of the Corporation (the Offering) through a syndicate of underwriters led by Cantor Fitzgerald Canada Corporation as the lead underwriter and sole bookrunner, and including RBC Dominion Securities Inc., National Bank Financial Inc., Scotia Capital Inc., Desjardins Securities Inc. and Echelon Wealth Partners Inc. (collectively, the Underwriters). Pursuant to the Offering, Prometic issued 31,250,000 common shares of the Corporation at a price of $1.70 per share for gross proceeds of $53,125,000.

In addition, Prometic completed a concurrent, non-brokered private placement of 5,045,369 common shares of the Corporation at a price of $1.70 per common share (the Private Placement) with SALP, an investment vehicle of Peter J. Thomson, following the exercise by SALP of its pre-emptive right to participate in any future public offering of Prometic's common shares. The $8.6 million in proceeds from the Private Placement were used to offset and reduce the total amount owed by Prometic to SALP pursuant to their loan agreement dated April 27, 2017.

Prometic, headquartered in Laval, Quebec, is a global biopharmaceutical company.

BLG represented Prometic with a team led by Pascal de Guise that included Yaniv Saragosti, Jean-Philippe Bertrand, Mélissa Azuelos, Lyne St. Pierre and Gianni Chiazzese.